• Illuccix, Telix's prostate cancer PET imaging agent, approved by UK's MHRA
• Illuccix represents a major advancement in prostate cancer management
• Reliable supply and scheduling flexibility to benefit UK patients and clinicians

Telix Pharmaceuticals Limited has announced that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix (kit for the preparation of gallium-68 gozetotide injection). Illuccix is indicated in the UK for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET. PSMA-PET imaging represents a major advancement in prostate cancer management, largely replacing conventional imaging methods as the standard of care after initial diagnosis and biochemical recurrence. The approval of Illuccix in the UK will help address the supply shortages of PSMA-PET imaging in the region and improve equity of access for patients. Illuccix's key advantages include its ability to be produced using a local generator, providing reliable service delivery and greater scheduling flexibility, including in non-metropolitan locations. Telix's exclusive distribution partner, Xiel Limited, will make Illuccix available to healthcare professionals across the UK and Ireland.